Aduro BioTech, Inc. has three interconnected and complementary vaccine platforms that provide breadth and depth in developing vaccines for cancer, infectious diseases and biodefense. The company's lead program is a randomized, controlled Phase 2 clinical trial of the sequential administration of Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer.